CIBC Private Wealth Group
RXRX icon

CIBC Private Wealth Group’s Recursion Pharmaceuticals RXRX Stock Holding History

CIBC Private Wealth Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$33 Buy
+8
New +$40 ﹤0.01% 3347
2024
Q1 		– Sell
-136,753
Closed -$1.35M – 3068
2023
Q4 		$1.35M Buy
+136,753
New +$975K ﹤0.01% 577

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

CIBC Private Wealth Group's RXRX Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q4 2025: 8 shares worth $33. The stake represents ﹤0.01% of the portfolio and ranks #3347 among its holdings. This is a return to the name: CIBC Private Wealth Group previously reported a position in RXRX as recently as Q4 2023.

CIBC Private Wealth Group first reported a position in RXRX in Q4 2023 and has held it in 2 quarters since. The position peaked at $1.35M in Q4 2023. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • CIBC Private Wealth Group held 8 shares of Recursion Pharmaceuticals worth $33 as of Q4 2025.
  • Recursion Pharmaceuticals was a new CIBC Private Wealth Group position in Q4 2025.
  • Recursion Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3347 holding.
  • CIBC Private Wealth Group first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • CIBC Private Wealth Group's Recursion Pharmaceuticals position peaked at $1.35M in Q4 2023.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.